Actinium Pharmaceuticals Valuation
| ATNM Stock | USD 1.55 0.14 9.93% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Actinium Pharmaceuticals shows a prevailing Real Value of $2.35 per share. The current price of the firm is $1.55. Our model approximates the value of Actinium Pharmaceuticals from analyzing the firm fundamentals such as Operating Margin of (555.05) %, return on equity of -1.0, and Shares Outstanding of 31.2 M as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Actinium Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of Actinium Pharmaceuticals is based on 3 months time horizon. Increasing Actinium Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Actinium stock is determined by what a typical buyer is willing to pay for full or partial control of Actinium Pharmaceuticals. Since Actinium Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Actinium Stock. However, Actinium Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.55 | Real 2.35 | Hype 1.51 | Naive 1.64 |
The intrinsic value of Actinium Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Actinium Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Actinium Pharmaceuticals helps investors to forecast how Actinium stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Actinium Pharmaceuticals more accurately as focusing exclusively on Actinium Pharmaceuticals' fundamentals will not take into account other important factors: Actinium Pharmaceuticals Total Value Analysis
Actinium Pharmaceuticals is presently estimated to have valuation of (28.6 M) with market capitalization of 48.35 M, debt of 2.11 M, and cash on hands of 116.33 M. The negative valuation of Actinium Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Actinium Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(28.6 M) | 48.35 M | 2.11 M | 116.33 M |
Actinium Pharmaceuticals Investor Information
About 30.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.27. Some equities with similar Price to Book (P/B) outperform the market in the long run. Actinium Pharmaceuticals recorded a loss per share of 1.39. The entity last dividend was issued on the 11th of August 2020. The firm had 1:30 split on the 11th of August 2020. Based on the key indicators related to Actinium Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Actinium Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Actinium Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Actinium Pharmaceuticals has an asset utilization ratio of 0.0995 percent. This suggests that the Company is making $9.95E-4 for each dollar of assets. An increasing asset utilization means that Actinium Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Actinium Pharmaceuticals Ownership Allocation
Actinium Pharmaceuticals holds a total of 31.2 Million outstanding shares. Almost 68.56 percent of Actinium Pharmaceuticals outstanding shares are held by general public with 1.78 (percent) owned by insiders and only 29.66 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Actinium Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 81 K. Net Loss for the year was (48.82 M) with profit before overhead, payroll, taxes, and interest of 81 K.About Actinium Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Actinium Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Actinium Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Actinium Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Actinium Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Actinium Pharmaceuticals. We calculate exposure to Actinium Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Actinium Pharmaceuticals's related companies.Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. The company was incorporated in 2000 and is based in New York, New York. Actinium Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 32 people.
Actinium Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Actinium Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 26.6 M | |
| Forward Price Earnings | 6.8399 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.